Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Profit After Tax (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Profit After Tax data on record, last reported at -$320.6 million in Q1 2026.

  • On a quarterly basis, Profit After Tax fell 127.85% to -$320.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$946.5 million, a 85.73% decrease, with the full-year FY2025 number at -$766.6 million, down 65.25% from a year prior.
  • Profit After Tax reached -$320.6 million in Q1 2026 per PCVX's latest filing, down from -$246.5 million in the prior quarter.
  • Over the last five years, Profit After Tax for PCVX hit a ceiling of -$39.0 million in Q1 2022 and a floor of -$320.6 million in Q1 2026.
  • A 5-year average of -$128.1 million and a median of -$103.1 million in 2024 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: plummeted 173.26% in 2022, then increased 24.18% in 2024.
  • Tracing PCVX's Profit After Tax over 5 years: stood at -$78.0 million in 2022, then crashed by 131.65% to -$180.8 million in 2023, then grew by 24.18% to -$137.1 million in 2024, then plummeted by 79.83% to -$246.5 million in 2025, then plummeted by 30.07% to -$320.6 million in 2026.
  • Business Quant data shows Profit After Tax for PCVX at -$320.6 million in Q1 2026, -$246.5 million in Q4 2025, and -$212.8 million in Q3 2025.